Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2010-08-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 7376
- Registration Number
- NCT00399724
TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 373
- Registration Number
- NCT00399750
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia
- Conditions
- Prostatic Hyperplasia
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2009-10-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1177
- Registration Number
- NCT00399464
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Insulin Glulisine, Diabetes Mellitus Type 1
- First Posted Date
- 2006-11-09
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 104
- Registration Number
- NCT00397553
- Locations
- 🇷🇺
Sanofi-Aventis, Moscow, Russian Federation
Acceptability Dermacyd Wipes - Lactoserum - Hygiene
- Conditions
- Hygiene
- First Posted Date
- 2006-11-09
- Last Posted Date
- 2008-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT00397527
- Locations
- 🇧🇷
Sanofi-Aventis, São Paulo, Brazil
Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder
- Conditions
- Anxiety Disorders
- First Posted Date
- 2006-11-08
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 257
- Registration Number
- NCT00397098
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation
- Conditions
- Heart Defects, Congenital
- Interventions
- Drug: placebo
- First Posted Date
- 2006-11-08
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 906
- Registration Number
- NCT00396877
- Locations
- 🇨🇳
Sanofi-Aventis Administrative Office, Taipei, Taiwan
🇬🇧Sanofi-Aventis Admnistrative Office, Guildford Surrey, United Kingdom
🇹🇭Sanofi-Aventis Administraive Office, Bangkok, Thailand
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
- Conditions
- Ovarian Neoplasms
- Interventions
- First Posted Date
- 2006-11-07
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT00396591
- Locations
- 🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden
Efficacy Study of Pristinamycin Versus Amoxicillin to Treat Tonsillitis Induced by Streptococcus in Children
- First Posted Date
- 2006-10-29
- Last Posted Date
- 2009-03-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 395
- Registration Number
- NCT00393744
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children
- Conditions
- Orthomyxoviridae InfectionInfluenzaMyxovirus Infection
- Interventions
- Biological: Split, Inactivated, Trivalent Influenza VaccineBiological: Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)
- First Posted Date
- 2006-10-24
- Last Posted Date
- 2011-12-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 520
- Registration Number
- NCT00391391